BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Immix Biopharma (IMMX)Immix BiopharmaConference / presentation

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1:

12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs)

1 patient with prior...

Related news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

SNDXSyndax Pharmaceuticals2026-06-11 11:00 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

IMMXImmix Biopharma2026-05-22 22:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-22 17:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
13.66 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States